Physician profile
Balu Chandra
NPI 1588623342
$10,315.55
in general payments reported to CMS, 2019-2025
39 companies · $1,634 in 2025
The $1,634 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,851 · 2020: $471 · 2021: $1,291 · 2022: $1,360 · 2023: $1,318 · 2024: $2,391 · 2025: $1,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,213 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,212.50 |
| Education | $130.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,747.97 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,122.80 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $956.49 | 2019-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $877.39 | 2019-2023 | Watchman Access System |
| Janssen Biotech, INC. | $658.42 | 2019-2025 | Stelara, Tremfya |
| Celgene Corporation | $594.42 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $376.20 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $304.09 | 2023-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $255.68 | 2021-2023 | Zeposia |
| Celltrion USA INC. | $208.99 | 2023-2025 | Zymfentra, Vegzelma |
| Conmed Corporation | $189.38 | 2024 | Conmed Eus |
| Enterra Medical, INC. | $172.96 | 2024 | |
| Axonics, INC. | $170.01 | 2024 | Axonics |
| Merck Sharp & Dohme LLC | $162.67 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $157.26 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $148.60 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $137.08 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $136.90 | 2022-2023 | Dupixent |
| Pfizer INC. | $133.02 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $105.95 | 2019-2020 | |
| Braintree Laboratories, INC. | $103.12 | 2020-2022 | |
| Qol Medical, LLC | $88.50 | 2019-2023 | Sucraid |
| Aimmune Therapeutics, INC. | $65.36 | 2024 | |
| Allergan, INC. | $50.18 | 2019 | |
| Nestle Healthcare Nutrition INC. | $49.32 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $49.20 | 2023 | Clenpiq, Rebyota |
| Madrigal Pharmaceuticals | $47.61 | 2024-2025 | Resmetirom, Rezdiffra |
| Shionogi INC | $46.85 | 2019-2020 | |
| Ardelyx, INC. | $43.11 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $28.67 | 2019-2020 | |
| Novo Nordisk INC | $21.95 | 2025 | Wegovy |
| Vivus LLC | $19.09 | 2025 | Pancreaze |
| Evoke Pharma, INC. | $17.53 | 2022 | |
| Amag Pharmaceuticals, INC. | $17.22 | 2022 | |
| Medtronic Vascular, INC. | $17.10 | 2019 | |
| Sandoz INC. | $13.71 | 2024 | |
| Ethicon US, LLC | $11.98 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $8.77 | 2021-2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,175.01 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Balu Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.